Johnson & Johnson to Acquire Abiomed

Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire ...

Related Keywords

United States ,Massachusetts ,Michael Bodner ,Johnson Plaza ,Michaelr Minogue ,Johnson Medtech ,Joaquin Duato ,Abiomed Breethe ,Ashley Mcevoy ,Johnson ,Biosense Webster ,Office Of The Corporate ,Jp Morgan Securities ,Exchange Commission ,Abiomed ,Sullivan Cromwell ,Goldman Sachs Co ,Swaine Moore ,Abiomed Inc ,Strengthens Johnson ,Medtech Business ,Bring Lifesaving Innovations ,More Patients ,Enhance Johnson ,Long Term Sales ,Earnings Growth ,Adjusted Earnings ,Discuss Details ,Chief Executive Officer ,Executive Vice President ,Worldwide Chairman ,Chief Executive ,Merger Sub ,Andrew Greenfield ,Chief Commercial Officer ,Interventional Cardiovascular ,Abbott Vascular ,Worldwide President ,Biosense Webster Electrophysiology ,Impella Connect ,Automated Impella Controller ,Hart Scott Rodino Antitrust Improvements Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Corporate Secretary ,Stone Johnson ,New Brunswick ,